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Purpose: To evaluate the interobserver variability of gross tumor volume (GTV) - delineation of Dominant
Intraprostatic Lesions (DIPL) in patients with prostate cancer using published MRI criteria for multiparametric MRI
at 3 Tesla by 6 different observers.
Material and methods: 90 GTV-datasets based on 15 multiparametric MRI sequences (T2w, diffusion weighted
(DWI) and dynamic contrast enhanced (DCE)) of 5 patients with prostate cancer were generated for GTV-delineation
of DIPL by 6 observers. The reference GTV-dataset was contoured by a radiologist with expertise in diagnostic
imaging of prostate cancer using MRI. Subsequent GTV-delineation was performed by 5 radiation oncologists who
received teaching of MRI-features of primary prostate cancer before starting contouring session. GTV-datasets were
contoured using Oncentra MasterplanW and iplanW Net. For purposes of comparison GTV-datasets were imported
to the ArtiviewW platform (AquilabW), GTV-values and the similarity indices or Kappa indices (KI) were calculated
with the postulation that a KI > 0.7 indicates excellent, a KI > 0.6 to < 0.7 substantial and KI > 0.5 to < 0.6 moderate
agreement. Additionally all observers rated difficulties of contouring for each MRI-sequence using a 3 point rating
scale (1 = easy to delineate, 2 = minor difficulties, 3 = major difficulties).
Results: GTV contouring using T2w (KI-T2w = 0.61) and DCE images (KI-DCE = 0.63) resulted in substantial
agreement. GTV contouring using DWI images resulted in moderate agreement (KI-DWI = 0.51). KI-T2w and KI-DCE
was significantly higher than KI-DWI (p = 0.01 and p = 0.003). Degree of difficulty in contouring GTV was significantly
lower using T2w and DCE compared to DWI-sequences (both p < 0.0001). Analysis of delineation differences
revealed inadequate comparison of functional (DWI, DCE) to anatomical sequences (T2w) and lack of awareness of
non-specific imaging findings as a source of erroneous delineation.
Conclusions: Using T2w and DCE sequences at 3 Tesla for GTV-definition of DIPL in prostate cancer patients by
radiation oncologists with knowledge of MRI features results in substantial agreement compared to an experienced
MRI-radiologist, but for radiotherapy purposes higher KI are desirable, strengthen the need for expert surveillance.
DWI sequence for GTV delineation was considered as difficult in application.
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Radiotherapy (RT) of primary prostate cancer (PCa) has
been modified in the past decade by using image-guided
radiotherapy (IGRT) and intensity modulated radiother-
apy (IMRT) techniques [1]. Whole gland dose escalation
with IMRT proved to be safe in respect of acute and late
toxicities [2-4]. Although prostate cancer is typically a
multifocal disease, histopathologic studies revealed that
most patients with prostate cancer have at least one or
two dominant intraprostatic tumor lesions (DIPL) [5,6].
For patients scheduled for primary radical radiotherapy
obtaining high irradiation doses of the whole prostate are
crucial to achieve high biochemical and clinical control
rates [7]. However the risk of toxicity, especially in the
rectal mucosa inevitably increases with dose escalatation
[8], thus requiring highly precise and accurate radiation
techniques. There is evidence that local prostate cancer
recurrence after primary radiotherapy develops from the
origination of the primary tumor or from the initial dom-
inant intraprostatic tumor burden [9,10]. Experience with
IMRT has led to the concept of focal dose-escalation using
simultaneous integrated boost of DIPL. Local dose escal-
ation on DIPL may result in significant improved disease
control without increasing normal tissue complication
probability (mainly acute and chronic rectal mucositis/
proctitis). This therapeutic approach has been calculated
by Niyazi et al. in a mathematical model based on differ-
ent assumptions of responsiveness of prostate cancer to
irradiation and different sensitivities and specificities of
an appropriate imaging method considering choline
PET [11].
Many studies with histopathologic comparison on whole-
mount sections as reference standard have shown that
Magnetic Resonance Imaging (MRI) using anatomic and
functional sequences like Magnetic Resonance Spectros-
copy (MRS), Dynamic Contrast Enhanced MRI (DCE-
MRI) and Diffusion weighted Imaging (DWI) results in
high accuracies in detecting primary prostate cancer due
to excellent spatial resolution with clear depiction of anat-
omy/pathoanatomy in combination with visualization of
functional properties of prostatic lesions [12-23]. DWI-
MRI in conjunction with T2-weighted showed accuracies
of 81% and 89% at 1.5 Tesla respectively [17,18]. DCE-
MRI showed a sensitivity and specificity for identification
of cancer foci > 0.5 mL of 86% and 94%, respectively [19].
Furthermore a combination of two functional sequences
at 1.5 Tesla resulted in a significantly improved area under
the receiver operating characteristic (ROC) curve com-
pared to a single functional parameter when whole-mount
sections with histologically defined tumor outlines were
used as reference standard. Using the combination of ap-
parent diffusion coefficient and initial area under the
gadolinium plasma concentration-time curve for detection
of cancer foci resulted in an area under the ROC curve of0.94 reflecting high accuracy. Combination of all three
functional parameters (DWI, DCE-MRI and MRS) showed
no further improvement [20]. Using T2w sequences at 3
Tesla results in reported sensitivities and specificities of
80%–88% and 96%–100%, respectively [24]. Prostate im-
aging at 3 Tesla benefits from higher signal to noise ra-
tio (SNR), enables higher quality imaging than obtained
at 1.5 Tesla and moreover the use of an endorectal coil
can be obviated with satisfying image quality [25] and
without distortion of pelvic anatomy which is important
for radiotherapy planning [26]. Recently the European
Society of Urogenital Radiology (ESUR) published MR
guidelines for imaging in prostate cancer and structured
reporting [27].
MRI-Criteria to identify an intraprostatic tumor lesion
are different throughout the MRI-sequences [27]. Few
studies based on consensus reading of a radiologist and
radiation oncologist using functional MRI sequences for
definition of DIPL have shown that focal dose escalation
results in low acute toxicities [28,29] with better sparing
of the rectal wall [30].
We wondered if knowledge and application of MRI-
criteria (Table 1, that are close to the recent published
ESUR-criteria) of DIPL leads to identical GTV-definitions
by different radiation-oncologists in comparison to a radi-
ologist with special knowledge of prostate-MRI. Therefore
the aims of the study were threefold: first to analyze the
practicability of MRI-criteria that can be used to define a
DIPL in 3 Tesla MRI-sequences, second to evaluate the
interobserver variability of radiation-oncologists versus an
experienced radiologist and third to evaluate possible rea-
sons of increased interobserver-variabilities.
Methods
Patients
Patients referred for irradiation of histopathologic proven
primary prostate cancer and who received pre-therapeutic
multiparametric 3 Tesla MRI with MRI-identifiable pros-
tatic lesions that suggest malignancy according to the
MRI-criteria (Table 1) were selected from our database.
For this retrospective study, the University of Freiburg In-
stitutional Review Board waived the consent require-
ments. Patient characteristics were as follows:
1. Pat. No. 1, 73 years, cT2b cN0 M0, Gleason 3 + 4,
initial PSA 14.6 ng/mL
2. Pat. No. 2, 80 years, cT3b cN0 M0, Gleason 4 + 5,
initial PSA 10.4 ng/mL
3. Pat. No. 3, 63 years, cT2c cN0 M0, Gleason 3 + 4,
initial PSA 5.1 ng/mL
4. Pat. No. 4, 69 years, pT3b cN0 M0, Gleason 4 + 3,
initial PSA 9.1 ng/mL
5. Pat. No. 5, 71 years, cT3a cN0 M0, Gleason 3 + 4,
initial PSA 9.4 ng/mL
Table 1 Description of MRI criteria suggestive for malignancy or DIPL according to different MRI sequences
MRI sequence MRI criteria suggestive for malignancy or DIPL
T2w Peripheral zone: inhomogeneous, irregular, low-signal intensity lesion with unclear margins or diffuse
extension and mass effect.
Central gland (transition zone), [23] homogeneous low-signal intensity region with:
• Poorly defined or spiculated lesion margins
• Lack of a low-signal-intensity rim (seen commonly in association with benign adenomatous nodules),
• Interruption of the surgical pseudocapsule (transition zone–to–peripheral zone boundary of low signal intensity),
• Urethral or anterior fibromuscular stromal invasion, and
• Lenticular shape
Diffusion weighed (DWI, using
ADC-maps)
Round-ellipsoid low intensity regions are suggestive of prostate cancer lesions [21,22].
Potential limitation: the high prevalence of benign prostate hyperplasia (BPH) may lead to low intensity
nodules like cancerous tissue.
Dynamic contrast enhanced (DCE) Focus of asymmetric, early and intense enhancement with rapid washout compared to the background.
Potential limitation: enhancing prostatitis in the peripheral zone and enhancing BPH in the transition zone [32].
Rischke et al. Radiation Oncology 2013, 8:183 Page 3 of 12
http://www.ro-journal.com/content/8/1/183MRI Technique
All MRI scans were acquired on a 3 Tesla system (Trio
Tim, Siemens Medical Solutions, Erlangen, Germany),
equipped with surface phased array (Body Matrix, Sie-
mens Medical Solutions). Imaging was performed by the
following sequences:
T2-weighted turbo spin echo (TSE) sequences in the
axial, sagittal and coronal planes (repetition time [TR],
8000 ms; echo time [TE], 110 ms; flip angle 130; field of
view 170 × 170 mm; thickness 3 mm; section gap 0.3;
matrix, 256 × 256).
T1-weighted (TSE) series of the whole pelvis was then
obtained with the following parameters: repetition time
[TR], 816 ms; echo time [TE], 11 ms; flip angle 140; field
of view 380 × 300 mm; thickness 3 mm; section gap 0.3;
matrix, 384 × 306.
DWI-sequence had repetition time [TR], 3100 ms; echo
time [TE], 85 ms; b-factor 1000; field of view 220 × 220
mm; thickness 3 mm; section gap 0.3; matrix, 124 × 124.
The last series performed was a 3D, fast low-angle shot
(FLASH), T1-weighted spoiled gradient-echo sequence in
axial plane (TR, 3,96 ms; TE, 1.38 ms; flip angle 12,33,
field of view 340 × 265 mm, thickness 1.65 mm; section
gap 0; matrix, 384 × 300) to perform measurements in
rapid succession, immediately following completion of an
intravenous bolus injection of 0.1 ml/kg gadopentetate
dimeglumine (Multihance, Bracco) using a power injector
(Medtron) at 3 ml/s followed by a 30 ml saline flush, 54
contrast-enhanced sets of images were acquired sequen-
tially without a delay between acquisitions, therefore time
resolution was 7 seconds.
Image analysis
Dicom datasets of T2w, DWI and DCE MRI-sequences of
each patient were imported into a RT-planning system
(Oncentra MasterplanW or iplanW Net), that is used in daily
routine ensuring familiarity with the delineation process.Slices from the DCE-image-series with visually deter-
minated early peak enhancement in suspicious lesions, ap-
propriate for delineation, were preselected by the expert
radiologist before import into the RT-planning system.
All radiation oncologists, familiar with delineation of
the prostate as whole organ using MRI scans, attended
two 1h-teaching lectures, in which prostate anatomy and
biophysical principles of anatomic and functional MRI-
sequences (Table 2, [27,31-40]) and the published cri-
teria suggestive for malignancy (Table 1, [21-23,32])
were demonstrated and explained by a radiologist with 8
years of experience of urogenital radiologic imaging es-
pecially prostate MRI. Interactive discussions of case
studies taken from the literature and from the own de-
partment was an integral part of the lecture.
In addition to visual analyses of DCE-MRI images calcu-
lated iAUC60 values [40] were converted into pseu-
docolour parametric maps and overlaid to the anatomic
T2-weighted images to support reading of the DCE-
images (example, see Figure 1).
The contouring radiation oncologist had access to the
MRI-report and the clinical staging parameters for each
of the five selected patients with histopathologically
(biopsy) verified prostate cancer. All radiation oncolo-
gists were equipped with a hand-out containing a sum-
mary of the above listed delineation criteria for the
different sequences (Table 1) and an atlas of typical patho-
logic findings available at hand when performing delinea-
tion on their own. First the GTV1 was contoured on the
T2w images (violet colour), second GTV2 was contoured
on the DWI-images (red colour) and third GTV3 was de-
lineated in the DCE-image-series (yellow colour) by each
radiation oncologist (observer) and the expert radiologist
(reference-dataset). Using the Oncentra MasterplanW of
iplanW Net fusion tool the T2w images were permanently
underlaid to the functional sequences (DWI, DCE) with
user enabled variable opacity for proper visualization of
Table 2 Description of biophysical principles and image characteristics of different MRI sequences
MRI sequence Biophysical principles and image characteristics
T2w Normal peripheral zone contains relatively high proton density, leading to a homogeneous high signal intensity.
Linear, wedge-shaped, or oval low-signal intensity lesions may be present but are considered non-malignant [31].
Normal central gland: variable amounts of intermediate signal intensity, which is often replaced by well-circumscribed
hyperplastic nodules of BPH with variable signal intensity [32-34].
Diffusion weighed (DWI) DWI-MRI measures the Brownian motion of water molecules. Reduced diffusion of water in prostate cancer is
attributed to the increased cellularity of malignant lesions, with reduction of the extracellular space and restriction of
the motion of a larger portion of water molecules to the intracellular space [35]. The amount of diffusion in tissue is
determined quantitatively by the apparent diffusion coefficient (ADC) [32]. Lower ADC values present malignant
lesions encoded by lower signal intensity (similar to T2w images). Similar to T2w-images detection of prostate cancer
in the peripheral zone is more accurate than in the transitional zone, where the high prevalence of benign prostate
hyperplasia (BPH) may lead to reduced ADC values like cancerous tissue. Higher Gleason score is associated with
decreased ADC, likely due to the dedifferentiated infiltrative growth of these tumors [36,37]. DWI-image quality and
contrast resolution may be hampered by tumor characteristics (e.g. low to intermediate Gleason score), susceptibility
artefacts due to magnetic field inhomogeneity and reduced in-plane resolution [27,32].
Dynamic contrast
enhanced (DCE)
DCE-MRI can visualize increased tumor vascularity in prostate cancer lesions. Prostate cancer lesions typically
demonstrate early, rapid and intense enhancement with quick wash-out [38,39]. Tumor vessels are different from
physiological vessels and typically have a higher permeability leading to contrast agent leakage in the extracellular-
extravascular space. DCE MR images need to be evaluated by direct visual interpretation of dynamic enhanced T1-
weighted images. Potential limitations of DCE-MRI are that it may not reliably differentiate prostatitis in the peripheral
zone and transition zone tumors from BPH [32]. Second signal intensity may be analysed using time-signal
parameters, e.g. determining peak enhancement or calculation of initial area under the curve in the first 60 seconds
(iAUC60) [40].
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1 to GTV 3 was started it was accomplished in one ses-
sion for each patient. Observers were instructed not to
compare DWI vs. DCE contours as an aim of the study
was not to generate a consensus volume but to evaluate
how each functional sequence is suitable for application
of MRI-criteria by a radiation oncologist. However ob-
servers were instructed to compare functional to anatom-
ical T2w sequence with respect to anatomy and organ
borders. Each observer rated difficulties of contouringFigure 1 Patient No. 4. iAUC60 values are converted into pseudocolor pa
reading of the DCE-images.according to the used MRI-sequence using a 3-point
scale rating scale (1 = easy to delineate, 2 = minor diffi-
culties, 3 = major difficulties). Finally 90 GTV-datasets
with definition of DIPL based on 5 patients, each exam-
ined with 3 different MRI-sequences were generated by
6 observers.
Statistics
For comparison purposes GTV datasets were imported
to the ArtiviewW platform (AquilabW). Using ArtiviewW-rametric maps and overlaid to the anatomic T2w images to support
Table 4 Shows different GTV summarized for all patients
GTV-Volumina T2w [ml] DWI [ml] DCE [ml]
Mean 4.3 4.4 5.3
Median 3.6 3.9 4.0
SD 2.3 2.5 3.4
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were calculated. Kappa statistic is currently the standard
to analyze reproducibility between to observers based on
binary questions [41] including digital (pixel based) im-
aging [42]. Kappa-index reflects agreement on pixel-by-
pixel basis with chance correction. It is defined by Kappa =
Po - Pc/1 – Pc, in which Po is the observed percentage
of agreement (the percentage of targets (pixels) rated the
same by different observers) and Pc is the percent of
agreement that would occur by chance alone [42].
According to the study it describes the ratio between the
intersection of the delineated volume for a given observer
x with its corresponding reference volume and their aver-
age. A Kappa-value of 1 indicates perfect agreement,
Kappa = 0 indicates agreement equal to pure chance. It is
generally accepted that Kappa > 0.7 indicates excellent
agreement [42], although others suggested interpretation
of kappa-values from 0.41 to 0.6 as moderate, from 0.61 to
0.8 as substantial and > 0.81 as excellent [43]. All contours
were reviewed to analyze reasons for differences in GTV
delineation. Statistical analysis was done by Mann–Whit-
ney-Test with a significance level at 0.05 (IBM-SPSS-STA-
TISTICS-Version19 Software).
Results
Different MRI-sequences lead to different GTV created by
6 observers within the same patient. Data on different
GTV results are given in Tables 3 and 4, there were no
statistical difference between the different GTV results for
each sequence and for all patients together (Table 4,
Figure 2). The Kappa-indices throughout the three differ-
ent MRI-sequences are listed in Table 5. At T2w a KI > 0.6
had been obtained in 15 of 25 GTV-definitions indicating
substantial to excellent agreement in 60%. At DWI a KI >
0.6 had been obtained in 6 of 25 GTV-definitions, indicat-
ing substantial to excellent agreement in 24%. At DCE a
KI > 0.6 had been obtained in 18 of 25 GTV-definitions in-
dicating substantial to excellent agreement in 72% of
contoured GTV with the reference contour. Mean KI at
T2w and DCE was 0.61 (SD: 0.12) and 0.63 (SD: 0.12) re-
spectively. Mean KI at DWI was 0.51 (SD: 0.15). Both KI-
T2w and KI-DCE were significantly higher than KI-DWI,
p = 0.01 (CI: 0.02-0.18) and p = 0.0027 (CI: 0.2-0.04),Table 3 Median, mean and standard deviation values of the G
observer) upon three different MRI-sequences for each patien
T2w [ml]
Median Mean SD Median
Pat. No1 3.7 4.1 1.5 4.0
Pat. No2 6.7 6.8 2.5 8.1
Pat. No3 2.0 2.1 0.5 1.8
Pat. No4 4.7 5.2 1.7 5.2
Pat. No5 3.4 3.2 1.3 2.9respectively (Figure 3). Rating score quotient was at T2w
1.76 (SD: 0.43), at DCE 1.53 (SD:0.51) and at DWI 2.6
(SD: 0.62). The degree of difficulty in contouring GTV
was significantly lower using T2w and DCE compared to
DWI-sequences, p < 0.0001 (CI: 1.11-0.56) respectively
p < 0.001 (CI:0.77-1.36) (Figure 4).
All contours were reviewed to analyze reasons for dif-
ferences in GTV delineation. Figure 5 (Patient No. 1)
shows that T2w-GTV-delineation resulted in high KI
compared to DCE-GTV-delineation (Table 5). The rea-
son for this was widely distributed symmetric contrast
enhancement in both prostate lobes (Figure 5, arrow in
the right picture) causing confusion concerning DIPL
borders. Symmetric enhancement at DCE without corre-
sponding criteria of DIPL in other sequences (including
T2w as required by the delineation-instructions) should
raise suspicion of the presence of rather benign changes
such as prostatitis in the peripheral zone or BPH in the
transition zone [32]. Figure 6 (Patient No. 2) demon-
strates the reason for a significant different delineation
contour owed to inadequately comparison of the se-
quences to each other. Figure 6, left picture, shows a
transversal slice through prostate base and adjacent sem-
inal vesicles, the diffuse low signal intensity forced two
observers to include the junction of seminal vesicles in
the prostate base (red contours) into the GTV at T2w
and DWI images (latter not shown). This was based on
the assumption that this low signal intensity is suggest-
ive of malignancy but no enhancement can be seen at
DCE and the prostate base should not be considered to
be infiltrated by the enhancing DIPL (Figure 6, right
picture). Figure 7 (Patient No. 3) shows the difference
between DWI and DCE used for GTV-delineation;
DWI-GTV-delineation (red contours) resulted in a high
interobserver variability/low KI compared to DCE-GTV-
delineation, where all observers including referenceTV contoured by 6 observers (including reference
t
DWI [ml] DCE [ml]
Mean SD Median Mean SD
3.8 1.6 3.3 4.7 4.2
7.0 2.8 7.3 8.4 3.1
2.6 2.5 2.3 2.7 0.9
5.3 1.9 6.8 7.1 3.1
3.0 0.9 2.8 3.4 1.1






















Reference observer 1 1 1 1 1
Observer A 0,639 0,469 0,532 0,496 0,671
Observer B 0,736 0,695 0,724 0,471 0,646
Observer C 0,720 0,549 0,653 0,634 0,691
Observer D 0,652 0,762 0,579 0,748 0,605
Observer E 0,759 0,511 0,539 0,475 0,272













Reference observer 1 1 1 1 1
Observer A 0,561 0,315 0,222 0,593 0,603
Observer B 0,727 0,528 0,304 0,648 0,497
Observer C 0,582 0,568 0,337 0,477 0,563
Observer D 0,586 0,687 0,358 0,588 0,555
Observer E 0,692 0,470 0,237 0,343 0,672













Reference observer 1 1 1 1 1
Observer A 0,254 0,641 0,669 0,471 0,563
Observer B 0,737 0,653 0,640 0,717 0,687
Observer C 0,710 0,691 0,651 0,775 0,409
Observer D 0,476 0,651 0,746 0,798 0,679
Observer E 0,000 0,677 0,691 0,643 0,543
DCE Rating-score quotient 1,67 1,5 1,33 1,33 1,83
KI = Kappa-Index. KI-values > 0.6 are bold and regarded as substantial
agreement respectively. KI-values > 0.7 indicate excellent agreement with the
reference volume per definition (please methods section). Rating score
quotient is the average of rating points assigned by all observers (including
reference) (1 = easy to delineate, 2 = minor difficulties, 3 = major difficulties).
Figure 2 Box plots with median, standard deviation and range
values of the GTV contoured by 6 observers (including reference
observer) upon three different MRI-sequences for all patients.
There were no statistical difference between the different GTV results for
each sequence and for all patients together (n.s. = not significant).
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Figure 8 (Patient No. 4), above left and right, shows
an example of excellent KI of DCE-GTV-delineation.
Figure 8 (below left and right) two observers erroneously
delineated laterally adjacent periprostatic vascular struc-
tures. Figure 9 (Patient No. 5) a delineation contour ex-
ceeds the organ contour of the prostate gland by far as
one observer who failed to correlate the DWI image
(Figure 9, left) with the corresponding T2w image
(Figure 9, right). Figure 9 also demonstrates that if all
observers would have had performed comparison with
the anatomic conditions no GTV would contain the high
signal intense area (arrows in Figure 9, left), that is equiva-
lent to unremarkable seminal vesicles at the base of pros-
tate gland.
Discussion
The strategy of focal dose escalation to DIPL within the
prostate to improve local tumor control and outcome of
primarily irradiated prostate cancer patients has gained in-
creasing interest in the past decade [11,28-30,44]. A large
multicentre randomized trial has been initiated that com-
pares focal dose escalation based on multiparametric MRI
findings vs. standard whole gland irradiation. In this trial
GTV-delineation is performed by experts in the field of
multiparametric prostate-MRI [45].
Other ongoing trials also use MRI to define the
GTV for focal dose escalation (e.g. ‘Tumor TARGET Pros-
tate Cancer’ (NCT01802242) or ‘The HEIGHT Trial’(NCT01411332)). Many studies using a combination of
anatomic with functional MRI sequences for detection of
DIPL having whole-mount histopathologic as reference
resulted in the definition of MRI guidelines by an expert
panel [27]. However published anatomic and functional
MRI criteria for DIPL have not yet been used in terms of
GTV-delineation by different radiation oncologists to
elucidate feasibility and potential confounding factors
throughout application in clinical practice. To the best of
our knowledge this is the first study that compares
interobserver variability using multiparametric MRI for
GTV-Definition of DIPL in patients with prostate cancer.
The GTV-volumes were similar throughout the differ-
ent MRI-sequences, although increased standard devia-
tions indicate delineation difficulties in some sequences
Figure 4 Rating score Quotient at T2w, DCE and DWI. Degree of
difficulty in contouring GTV was significantly lower using T2w and
DCE compared to DWI-sequences, ***p < 0.0001 (CI: 1.11-0.56)
respectively ***p < 0.001 (CI:0.77-1.36).
Figure 3 KI-T2w and KI-DCE was significantly higher than
KI-DWI, *p = 0.01 (CI: 0.02-0.18) and **p = 0.0027 (CI: 0.2-0.04),
respectively.
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comprehensive but tailored teaching of radiation oncolo-
gists about published and widely accepted MRI criteria of
DIPL results in substantial to partially excellent agreement
compared to an experienced prostate MRI reader depend-
ing on the used MRI-sequences (Table 5). Mean KI at
T2w and DCE was significantly higher than KI-DWI
(Figure 3). Additionally we measured applicability with a
3-point rating score describing difficulties of the delinea-
tion process. We found that the degree of difficulty in
contouring the GTV was significantly lower using T2w
and DCE compared to DWI-sequences (p < 0.0001 for
both, Figure 4).
We highlight some important aspects of the delinea-
tion process. First, it is important to have anatomic de-
tails provided by the T2w-sequence as an underlyingFigure 5 (Patient No.1). Transversal slices through the middle prostate gl
picture show T2w (violet contour) and DWI (red contour) based GTV-deline
contour) based GTV-delineation; the arrow indicates delineation of non-spe
the right side.dataset to fuse with the functional dataset (DWI, DCE).
Complementary morphologic information is essential to
avoid delineation errors exceeding organ contours like
those that are described in Figures 8 and 9. Second,
different signal characteristics of functional sequences
should be critically compared to each other to check for
possible non-specific findings like bilateral symmetric
contrast enhancement described in Figure 5. Further-
more one has to keep in mind that the specificity of func-
tional MRI-sequences is higher than the anatomic T2w
sequences [12-23], but depends not only on the signal
characteristic but also on the signal distribution in con-
text with the surrounding anatomy [21,22,32]. Inad-
equate comparison may lead to delineation errors as
described in Figures 6 and 9. T2w-sequences have aand; left = T2w-, middle = DWI-, right = DCE-sequence. Left and middle
ation respectively. On the right image additionally DCE (yellow
cific enhancement by two observers in the left gland symmetric to
Figure 6 (Patient No. 2). Transversal slices through prostate base and adjacent seminal vesicles; left = T2w-, right = DCE-sequence. Left: the
diffuse low signal intensity forced two observers to include the junction of seminal vesicles in the prostate base (violet and red contours, arrows)
into the GTV at T2w images. Right: DCE based GTV-definition (yellow contours).
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sequences [46-48]. However GTV-delineations done by
DWI and DCE-MRI sometimes may not co-localize well
in tumor-bearing prostate glands because both parame-
ters reflect different tissue properties that are associated
with the presence of tumor. To manage this problem
Groenendal et al. suggested if DWI and DCE give consist-
ent information, the delineation of a target can be straight-
forward, because there is a high probability that regions
identified by both modalities contain tumor tissue. When
the two imaging modalities give inconsistent information,
the probability that tumor is present is smaller. A practical
approach could be to treat the voxels on which the two
modalities agree as the GTV. In case only one of the two
modalities indicates a voxel as suspicious, the region could
be considered a ‘high-risk CTV’. One could choose not to
boost these regions, but in any case safe margins should
be applied around these regions [49].
Our study has some limitations. We selected 5 con-
secutive patients that received functional MRI at 3 Tesla
from our database with clearly visible DIPL. Depending
on the type of cancer, its growth pattern and patient spe-
cific conditions (e.g. antiandrogen therapy prior to MRI
[50]) visualization of DIPL may be hampered by difficul-
ties to distinguish or by lacking distinct lesions [28]. 3
Tesla functional MRI is currently the imaging deviceFigure 7 (Patient No. 3). Transversal slices through the middle of the pro
GTV-delineation (red contours). Right: DCE based GTV-delineation (yellow cwith the highest accuracy in detection of DIPL due to dif-
ferent functional sequences offering important additional
information about specific tissue characteristics. Mag-
netic resonance spectroscopy (MRS) – sequences were
not available, adding MRS-sequences would have led to
15 min extra examination time and is not part of the rou-
tine diagnostic work up in our radiology department.
Knowing the reported high specificity (but low sensitiv-
ity) of MRS to characterize prostate cancer nodules [51]
and the limited spatial resolution, we prefer image char-
acteristics of the two other functional MRI-sequences
(DCE, DWI) for GTV-delineation and comparison met-
rics. However preselection of DCE-image-series, of
iAUC60-derived maps and the ADC-maps by the refer-
ence radiologist may have introduced a bias in the image
analysis. In fact according to the ESUR-guidelines further
analyses of image data, e.g. comparison of ADC-maps
with b-value images (at > b800) and generating DCE-
enhancement curves in suspicious regions are useful to
more precisely characterize image findings. Future studies
may use the newly introduced PI-RADS scoring system to
describe DIPL. Standard of reference was predetermined
by a radiologist with thorough knowledge of imaging fea-
tures of prostate cancer using functional MRI but we did
not have a whole-mounted histopathologic reference
standard. Although GTV delineation was performedstate; left = DWI-, right = DCE-sequence. Left: DWI based
ontours). T2w-GTV-contours are not depicted for better survey.
Figure 8 (Patient No. 4). Transversal slices in the middle third (above) and near the prostate base (below) of the prostate gland; above/below
left = DCE-, above/below right = T2w-sequence. Above left and right: DCE based GTV-delineation (yellow contours) with high KI. Below left: two
observers erroneously delineated laterally adjacent enhancing periprostatic vascular structures near the prostate base (arrows indicating yellow
contours). Below right: arrows indicate presence of periprostatic vessels.
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http://www.ro-journal.com/content/8/1/183with caution by the reference radiologist it cannot be
ruled out that in the situation of low tumor to back-
ground contrast (e.g. Figure 7) the GTV was arbitrarily
delineated to some extent and does not necessarily rep-
resent the true tumor extension. It is important to
emphasize that the major goal in terms of dose escal-
ation is to define the approximate volume of the dom-
inant intraprostatic lesion, which will be irradiated with
a certain safety margin that corrects for intrafraction
organ movement and therefore submillimeter precision
will not necessarily translate in altered planning target
volumes (PTV). In fact it is always an individual deci-
sion whether dose escalation is feasible taking into ac-
count normal tissue dose constraints that may be
influenced significantly by individual factors [30].
The teaching lectures and hand-outs (Table 1) com-
prised all currently available information to perform theFigure 9 (Patient No. 5). Transversal slices through near the prostate base
contours) does not correspond to T2w based GTV-delineation (violet conto
Additionally erroneous delineation of unremarkable seminal vesicles (arrowrequired GTV-delineation. Our results do reflect that the
attending radiation oncologists did successfully delineate
GTV in some cases according to the MRI sequence. How-
ever our analysis also show that significant slips of the pen
do occur while GTV-delineation in different MRI se-
quences and comparison to each other is challenging and
therefore should not be used in a clinical setting without
expert surveillance. Segmentation algorithms may be use-
ful to reduce interobserver variability of prostate organ de-
lineation [52]. In addition Groenendaal et al. described a
logistic regression model that predicts tumor presence on
a voxel level in the peripheral zone of the prostate gland
based on ADC and K-trans values within a voxel. They
found a high correspondence of model and pathologic
findings at an AUC of 0.89 [53]. From the radiation-
oncologists point of view an imaging device that offers ob-
jective and reliable detection of DIPL seems strongly; left = DWI-, right = T2w-sequence. DWI based GTV-delineation (red
urs). Asterisk marks the erroneously contoured area in both pictures.
s in the left picture).
Rischke et al. Radiation Oncology 2013, 8:183 Page 10 of 12
http://www.ro-journal.com/content/8/1/183desirable. For this purpose the proposed statistic model
showing a high diagnostic performance may be a useful
tool for the peripheral zone were most of the tumors
occur [53].
MRI has been shown to be improve target delineation
[54,55] and isotropic voxels reduce delineation discrepan-
cies [56]. But even using established MRI-sequences
(T2w) for prostate organ delineation may result in signifi-
cant variability as was recently shown in a multi-observer,
-center and -sequence study based in T2w-sequences [57].
In this study Nyholm et al. found that the imaging se-
quence appears to have a large influence on the delinea-
tion variability. Interestingly they found that images with
optimal quality were associated with the largest delinea-
tion variability. They concluded that increased amount of
information increases the scope of interpretation and
hence the importance of training and experience. Our re-
sults lead to a similar conclusion that a second observer
(experienced radiologist) opinion is required until the
skills of functional MRI delineation have been developed
and trained by the radiation oncologists. Positron-
Emission-Tomography in combination with computed
tomography (PET/CT) may offer appropriate visualization
of functional properties depending on the radiotracer, but
experience with labelled choline in the untreated prostate
with presence of PCa showed conflicting results with lim-
ited accuracy [58-60]. In this respect new and highly spe-
cific radiotracers for prostate cancer imaging are required,
that are more appropriate for radiotherapy purposes [61].Conclusions
Using T2w and DCE sequences at 3 Tesla for GTV-
definition of DIPL in prostate cancer patients by radiation
oncologists with knowledge of MRI features results in
substantial agreement compared to an experienced MRI-
radiologist, but for radiotherapy purposes higher KI are
desirable. DWI sequences for GTV delineation were con-
sidered as difficult in application and resulted in only
moderate interobserver agreement. From the radiation
oncologists point of view GTV-delineation in different
MRI sequences and comparison to each other is challen-
ging and therefore should not be used in a clinical setting
without expert surveillance.Competing interest
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